TherapeuticsMD, Inc. (TXMD)
| Market Cap | 24.42M |
| Revenue (ttm) | 3.35M |
| Net Income (ttm) | 179,000 |
| Shares Out | 11.57M |
| EPS (ttm) | 0.02 |
| PE Ratio | 283.98 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,895 |
| Open | 2.010 |
| Previous Close | 2.030 |
| Day's Range | 2.010 - 2.150 |
| 52-Week Range | 0.981 - 2.950 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement... [Read more]
Financial Performance
In 2025, TherapeuticsMD's revenue was $3.02 million, an increase of 71.61% compared to the previous year's $1.76 million. Losses were -$569,000, -73.91% less than in 2024.
Financial StatementsNews
TherapeuticsMD reports Q1 EPS 1c vs. (6c) last year
Reports Q1 revenue $724K vs. $393K y/y. The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business…
TherapeuticsMD Announces First Quarter 2026 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Earnings release: Q1 2026
TherapeuticsMD released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
TherapeuticsMD Quarterly report: Q1 2026
TherapeuticsMD has published its Q1 2026 quarterly earnings report on May 12, 2026.
TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year
As of December 31, 2025, the Company’s cash and cash equivalents totaled $7.5 million.
TherapeuticsMD Announces Full Year 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Earnings release: Q4 2025
TherapeuticsMD released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
TherapeuticsMD Annual report: Q4 2025
TherapeuticsMD has published its Q4 2025 annual report on March 30, 2026.
TherapeuticsMD reports Q3 EPS 0c vs. (5c) last year
As of September 30, 2025, the Company’s cash and cash equivalents totaled $7.1 million. The Company “continues to evaluate a variety of strategic alternatives that may include, but not be…
TherapeuticsMD Announces Third Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Earnings release: Q3 2025
TherapeuticsMD released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
TherapeuticsMD Quarterly report: Q3 2025
TherapeuticsMD has published its Q3 2025 quarterly earnings report on November 6, 2025.
TherapeuticsMD Proxy statement: Proxy Filing
TherapeuticsMD filed a proxy statement on November 3, 2025, providing details for shareholder voting and corporate governance matters.
TherapeuticsMD Proxy statement: Proxy Filing
TherapeuticsMD filed a proxy statement on November 3, 2025, providing details for shareholder voting and corporate governance matters.
TherapeuticsMD Proxy statement: Proxy Filing
TherapeuticsMD filed a proxy statement on October 24, 2025, providing details for shareholder voting and corporate governance matters.
TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year
License revenue, primarily from the Mayne License Agreement, totaled $1.0 million for the second quarter of 2025, an increase of $0.7 million, compared to $234 thousand in license revenue for…
TherapeuticsMD Announces Second Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Quarterly report: Q2 2025
TherapeuticsMD has published its Q2 2025 quarterly earnings report on August 12, 2025.
TherapeuticsMD Earnings release: Q2 2025
TherapeuticsMD released its Q2 2025 earnings on August 12, 2025, summarizing the period's financial results.
TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic…
TherapeuticsMD Announces First Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Quarterly report: Q1 2025
TherapeuticsMD has published its Q1 2025 quarterly earnings report on May 13, 2025.
TherapeuticsMD Earnings release: Q1 2025
TherapeuticsMD released its Q1 2025 earnings on May 13, 2025, summarizing the period's financial results.
TherapeuticsMD Announces Full Year 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Annual report: Q4 2024
TherapeuticsMD has published its Q4 2024 annual report on March 27, 2025.